Exhibit 99.1



Xtant Medical Announces First Quarter 2020 Financial Results


BELGRADE, MT, May 7, 2020 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2020.


First Quarter 2020 Financial Highlights:


  Revenue for the first quarter of 2020 was $14.8 million, compared to $16.7 million for the prior year period

Operating expenses in the first quarter of 2020 were $11.0 million, compared to $11.5 million for the prior year period

Net loss incurred in the first quarter of 2020 was $2.5 million, compared to a net loss of $2.8 million for the prior year period

Non-GAAP Adjusted EBITDA for the first quarter of 2020 was $0.5 million, compared to $1.0 million for the prior year period


“First and foremost, we are grateful to the healthcare professionals, including many of our customers, who are tirelessly caring for patients on the front lines of the global COVID-19 pandemic,” said Sean Browne, President and CEO. “Sales for the first two months of the first quarter 2020 were tracking in-line with our expectations. However, as the COVID-19 outbreak escalated and various restrictions related to elective surgical procedures were implemented, we saw a dramatic decline in sales during March. As almost all of our spinal procedures are considered elective, we expect significant reductions in our revenue will continue until such restrictions are lifted. To that end, we proactively implemented several initiatives to reduce costs and preserve our cash, which should enable us to navigate this unprecedented challenge.”


COVID-19 Response


In response to the COVID-19 pandemic, Xtant Medical identified four areas that should help to maintain business continuity and emerge from this health crisis in a position of strength:


  1. Employees – Prioritized keeping employees and their families safe and healthy through social distancing and work from home procedures where possible.
  2. Expenses – Enacted an extensive cost reduction program to preserve cash, which included workforce reductions and furloughs, across the board compensation and related benefits decreases, and significant reductions in both capital expenditures and discretionary spending.
  3. Inventory – Replenished inventory levels to minimize risk for stockouts going forward.
  4. Organization – Initiated a strategy to reorganize the structure and operations of the business to improve overall efficiency.


“Although it was a difficult decision to reduce our workforce, we believe it was necessary in order to preserve capital and operate as a leaner organization during this unprecedented global health crisis,” continued Mr. Browne. “We have a unique opportunity to further our mission of ‘honoring the gift of donation, by allowing our patients the ability to live as full a life as possible.’ Through our actions, I believe we will be in a better position to fulfill this as conditions normalize.”





First Quarter 2020 Financial Results


Total revenue for the three months ended March 31, 2020 was $14.8 million, which represents a decrease of 11.6% compared to $16.7 million in the same quarter of the prior year. The decrease in revenue is attributed primarily to the impact of COVID-19 and the sudden drop in elective procedures beginning in early March as result of the pandemic.


Gross margin for the first quarter of 2020 was 65.0%, compared to 64.6% for the same period in 2019.


Operating expenses for the first quarter of 2020 were $11.0 million, compared to $11.5 million for the first quarter of 2019. The decrease was primarily due to lower sales commissions of $0.4 million attributed to lower sales, lower expenses for legal and consulting services totaling $0.5 million, and legal settlement expenses of $0.5 million reserved in the first quarter of 2019, offset partially by severance expenses totaling $0.7 million.


First quarter 2020 net loss was $2.5 million, or $0.19 per share, compared to first quarter 2019 net loss of $2.8 million, or $0.21 per share.


Non-GAAP Adjusted EBITDA for the first quarter of 2020 was $0.5 million compared to $1.0 million for the same period in 2019. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income taxes, and as further adjusted to add back in or exclude, as applicable, non-cash special charges, provision for losses on inventory and accounts receivable, non-cash compensation, change in warrant derivative liability, separation related expenses, and litigation settlement reserves. A calculation and reconciliation of non-GAAP Adjusted EBITDA to net loss can be found in the attached financial tables.


Conference Call


Xtant Medical will host a webcast and conference call to discuss the first quarter 2020 financial results on Thursday, May 7, 2020 at 9:00 AM ET. To access the webcast, Click Here. To access the conference call, dial 877-407-6184 within the U.S. or 201-389-0877 outside the U.S. A replay of the call will be available at www.xtantmedical.com, under “Investor Info.”


About Xtant Medical Holdings, Inc.


Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.


The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.





Non-GAAP Financial Measures


To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.


Important Cautions Regarding Forward-looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “continue,” “future,” “will,” “potential” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s expectations regarding the effect of the COVID-19 pandemic on the Company’s business and future revenue. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the effect of the COVID-19 pandemic on the Company’s business, operating results and financial condition; the Company’s future operating results and financial performance; the ability to increase or maintain revenue; the ability to remain competitive; the ability to innovate and develop new products; the effect of management changes and the ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC) on March 5, 2020 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 anticipated to be filed with the SEC. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.


Investor Relations Contact


David Carey

Lazar FINN

Ph: 212-867-1762

Email: dcarey@finnpartners.com







(In thousands, except number of shares and par value)


   March 31, 2020   December 31, 2019 
Current Assets:          
Cash and cash equivalents  $3,239   $5,237 
Trade accounts receivable, net of allowance for doubtful accounts of $500 and $2,140, respectively   9,743    10,124 
Inventories   18,044    16,101 
Prepaid and other current assets   1,084    784 
Total current assets   32,110    32,246 
Property and equipment, net   4,303    4,695 
Right-of -use asset, net   1,999    2,100 
Goodwill   3,205    3,205 
Intangible assets, net   500    515 
Other assets   434    394 
Total Assets  $42,551   $43,155 
Current Liabilities:          
Accounts payable  $3,609   $2,188 
Accrued liabilities   5,910    6,625 
Warrant derivative liability   1    7 
Current portion of lease liability   401    394 
Current portion of financing lease obligations   138    176 
Total current liabilities   10,059    9,390 
Long-term Liabilities:          
Lease liability, less current portion   1,623    1,726 
Financing lease obligation, less current portion   -    - 
Long-term debt, less issuance costs   77,345    76,244 
Total Liabilities   89,027    87,360 
Stockholders’ Equity (Deficit)          
Preferred stock   -    - 
Common stock   -    - 
Additional paid-in capital   179,330    179,061 
Accumulated deficit   (225,806)   (223,266)
Total Stockholders’ Equity (Deficit)   (46,476)   (44,205)
Total Liabilities & Stockholders’ Equity (Deficit)  $42,551   $43,155 







(Unaudited, in thousands, except number of shares and per share amounts)


   Three Months Ended March 31, 
   2020   2019 
Orthopedic product sales  $14,735   $16,686 
Other revenue   43    40 
Total revenue   14,778    16,726 
Cost of sales   5,165    5,913 
Gross profit   9,613    10,813 
Gross profit %   65.0%   64.6%
Operating expenses          
General and administrative   4,319    4,477 
Sales and marketing   6,413    6,742 
Research and development   245    262 
    10,977    11,481 
Loss from operations   (1,364)   (668)
Other (expense) income          
Interest expense   (1,108)   (2,018)
Change in warrant derivative liability   6    (15)
Other (expense) income   (5)   (75)
Total Other (Expense) Income   (1,107)   (2,108)
Net Loss from Operations Before Provision for Income Taxes   (2,471)   (2,776)
Provision for income taxes          
Current and deferred   (22)   (23)
Net Loss from Operations  $(2,493)  $(2,799)
Net loss per share:          
Basic  $(0.19)  $(0.21)
Dilutive  $(0.19)  $(0.21)
Shares used in the computation:          
Basic   13,175,345    13,170,721 
Dilutive   13,175,345    13,170,721 







(Unaudited, in thousands)


   Three Months Ended March 31, 
    2020    2019 
Operating activities:          
Net loss  $(2,493)  $(2,799)
Adjustments to reconcile net loss to net cash provided by operating activities:          
Depreciation and amortization   685    776 
(Gain) loss on disposal of fixed assets   (105)   116 
Non-cash interest   1,101    1,991 
Non-cash rent expense   4    - 
Stock-based compensation   269    122 
Provision for reserve on accounts receivable   138    94 
Provision for excess and obsolete inventory   31    153 
Change in warrant derivative liability   (6)   15 
Changes in operating assets and liabilities:          
Accounts receivable   195    403 
Inventories   (1,974)   623 
Prepaid and other assets   (340)   146 
Accounts payable   1,421    (429)
Accrued liabilities   (715)   (721)
Net cash provided by (used in) operating activities   (1,789)   490 
Investing activities:          
Purchases of property and equipment   (258)   (137)
Proceeds from sale of fixed assets   83    51 
Net cash used in investing activities   (175)   (86)
Financing activities:          
Payments on financing leases   (34)   (104)
Net cash provided by (used in) financing activities   (34)   (104)
Net change in cash and cash equivalents   (1,998)   300 
Cash and cash equivalents at beginning of period   5,237    6,797 
Cash and cash equivalents at end of period  $3,239   $7,097 







(Unaudited, in thousands)


   Three Months Ended March  31, 
   2020   2019 
Net Loss  $(2,493)  $(2,799)
Other expense   5    75 
Depreciation and amortization   685    776 
Interest expense   1,108    2,017 
Tax expense   22    23 
Non-GAAP EBITDA   (673)   92 
Non-GAAP EBITDA/Total revenue   -4.6%   0.6%
Provision for reserve on accounts receivable   138    94 
Provision for excess and obsolete inventory   31    153 
Stock-based compensation   269    122 
Change in warrant derivative liability   (6)   15 
Separation-related expenses   749    (21)
Litigation reserve   -    530 
Non-GAAP Adjusted EBITDA  $508   $985 
Non-GAAP Adjusted EBITDA/Total revenue   3.4%   5.9%




The following information was filed by Xtant Medical Holdings, Inc. (XTNT) on Thursday, May 7, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Xtant Medical Holdings, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Xtant Medical Holdings, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account